Proteomic analysis identifies argininosuccinate synthetase 1 and special AT-rich sequence binding protein 1 as reliable markers for the immunohistochemical distinction between WHO types A and B3 thymomas.
argininosuccinate synthetase 1
diagnosis
immunohistochemistry
mass spectrometry
pathology
special AT-rich sequence binding protein 1
thymoma
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
19
05
2023
received:
14
02
2023
accepted:
23
05
2023
medline:
13
9
2023
pubmed:
13
6
2023
entrez:
12
6
2023
Statut:
ppublish
Résumé
The reliable classification of type A versus type B3 thymomas has prognostic and therapeutic relevance, but can be problematic due to considerably overlapping morphology. No immunohistochemical markers aiding in this distinction have been published so far. We identified and quantified numerous differentially expressed proteins using an unbiased proteomic screen by mass spectrometry in pooled protein lysates from three type A and three type B3 thymomas. From these, candidates were validated in a larger series of paraffin-embedded type A and B3 thymomas. We identified argininosuccinate synthetase 1 (ASS1) and special AT-rich sequence binding protein 1 (SATB1) as highly discriminatory between 34 type A and 20 type B3 thymomas (94% sensitivity, 98% specificity and 96% accuracy). Although not the focus of this study, the same markers also proved helpful in the diagnosis of type AB (n = 14), B1 (n = 4) and B2 thymomas (n = 10). Mutually exclusive epithelial expression of ASS1 in 100% of type B3 thymomas and ectopic nuclear expression of SATB1 in 92% of type A thymomas support the distinction between type A and type B3 thymomas with 94% sensitivity, 98% specificity and 96% accuracy.
Substances chimiques
Argininosuccinate Synthase
EC 6.3.4.5
Matrix Attachment Region Binding Proteins
0
SATB1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
607-616Informations de copyright
© 2023 The Authors. Histopathology published by John Wiley & Sons Ltd.
Références
Marx A, Chan JKC, Chalabreysse L et al. The 2021 who classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J. Thorac. Oncol. 2022; 17; 200-213.
Radovich M, Pickering CR, Felau I et al. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 2018; 33; 244-258.e10.
Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, Committee EG. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015; 26(Suppl 5); v40-v55.
Nonaka D, Rosai J. Is there a spectrum of cytologic atypia in type a thymomas analogous to that seen in type b thymomas? A pilot study of 13 cases. Am. J. Surg. Pathol. 2012; 36; 889-894.
Chilosi M, Castelli P, Martignoni G et al. Neoplastic epithelial cells in a subset of human thymomas express the b cell-associated cd20 antigen. Am. J. Surg. Pathol. 1992; 16; 988-997.
Roden AC, Yi ES, Jenkins SM et al. Diagnostic significance of cell kinetic parameters in world health organization type A and B3 thymomas and thymic carcinomas. Hum. Pathol. 2015; 46; 17-25.
Petrini I, Meltzer PS, Kim IK et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat. Genet. 2014; 46; 844-849.
Marx A, Detterbeck F, Marom EM, Strobel P, Rajan A. Thymoma: introduction. In Marx A, Chan JK eds. Thoracic tumours. Lyon, France: International Agency for Research on Cancer, 2021.
Marx A, Strobel P, Badve SS et al. Itmig consensus statement on the use of the who histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J. Thorac. Oncol. 2014; 9; 596-611.
Burger T, Schaefer IM, Kuffer S et al. Metastatic type a thymoma: morphological and genetic correlation. Histopathology 2017; 70; 704-710.
Strobel P, Hartmann E, Rosenwald A et al. Corticomedullary differentiation and maturational arrest in thymomas. Histopathology 2014; 64; 557-566.
Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T. The mar-binding protein satb1 orchestrates temporal and spatial expression of multiple genes during t-cell development. Genes Dev. 2000; 14; 521-535.
Haines RJ, Pendleton LC, Eichler DC. Argininosuccinate synthase: at the center of arginine metabolism. Int. J. Biochem. Mol. Biol. 2011; 2; 8-23.
Goodwin BL, Solomonson LP, Eichler DC. Argininosuccinate synthase expression is required to maintain nitric oxide production and cell viability in aortic endothelial cells. J. Biol. Chem. 2004; 279; 18353-18360.
Haines RJ, Corbin KD, Pendleton LC, Meininger CJ, Eichler DC. Insulin transcriptionally regulates argininosuccinate synthase to maintain vascular endothelial function. Biochem. Biophys. Res. Commun. 2012; 421; 9-14.
Delage B, Fennell DA, Nicholson L et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int. J. Cancer 2010; 126; 2762-2772.
Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev VA, Kohwi Y. Genome organizing function of SATB1 in tumor progression. Semin. Cancer Biol. 2013; 23; 72-79.
Lena AM, Mancini M, di Val Cervo PR et al. Microrna-191 triggers keratinocytes senescence by SATB1 and CDK6 downregulation. Biochem. Biophys. Res. Commun. 2012; 423; 509-514.
Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008; 452; 187-193.